AlphAIAlphAI — Financial news for AI agents
stocktitan.netAUG 142 min read$CERS

Baker Bros. cuts Cerus Corporation (CERS) position to 3.2% ownership stake

Baker Bros. Advisors LP and related reporting persons filed Amendment No. 13 to a Schedule 13G showing beneficial ownership of 6,395,431 Cerus Corp (CERS) shares, or 3.2% of 201,457,000 shares outstanding as of June 30, 2026. Julian C. Baker and Felix J. Baker each report 19,864 shares individually, each totaling about 3.2%.

Original reporting
stocktitan.net
Published Aug 14, 2026, 8:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 9:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$CERS
Neutral
medium confidence
Mentioned
$CERS
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$CERSNeutralLow
01

Why it matters

The disclosure updates the market on who holds economic exposure and voting power, but it does not introduce new Cerus-specific catalysts such as trial results, guidance, financing, or regulatory actions.

02

Market read

Traders may treat this as a minor positioning/flow datapoint rather than a fundamental catalyst for CERS.

03

What to watch

Beneficial ownership can change via derivatives, transfers, or timing of reporting; without the prior amendment details, the direction and magnitude of the change versus the last filing are unclear.

Relevance 4/10Novelty 4/10Timing: as of the latest Schedule 13G/A filing (Amendment No. 13)

Background

The article summarizes an SEC Schedule 13G/A amendment reporting beneficial ownership in Cerus Corporation by Baker Bros. Advisors LP and related persons.

Company-level read

Ticker impact

$CERSNeutralMedium confidence
Context

Baker Bros. Advisors filed Schedule 13G/A Amendment No. 13 showing beneficial ownership of 3.2% of Cerus common stock.

Expected impact

Low near-term impact; any move is likely small and flow-driven rather than fundamental.

Evidence & confidence

The article provides a regulatory ownership disclosure (beneficial ownership and shares outstanding basis) without new operational, clinical, or financial guidance for Cerus.

Market effects

Sector

Minimal, since the disclosure is a single fund position change without sector-wide regulatory or clinical implications.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

A below-5% stake can still be meaningful if it reflects a new or rebalanced thesis, but the filing alone does not confirm intent or trading horizon.

Key entities

  • issuer
    Cerus Corporation

    US-listed company whose beneficial ownership stake is reported as 3.2% by Baker Bros. Advisors in the filing summary.

  • investor
    Baker Bros. Advisors LP

    Reporting person that filed Amendment No. 13 to Schedule 13G/A for Cerus common stock.

Read at source← All news

Related articles

NOV 3
$CERSMed

Cerus Q3 Earnings Call Highlights

Cerus reported Q3 EMEA revenue growth of 5%, impacted by geopolitical and currency headwinds. The company's RedeS study met primary efficacy endpoints, with full analysis expected soon. Cerus reaffirmed 2026 revenue guidance of $229M-$231M and reported positive adjusted EBITDA. The company is addressing regulatory questions from the FDA and ANSM. Cerus aims for GAAP profitability and plans to refresh its shelf registration statement.

finance.yahoo.com2 min
NOV 2
$CERSMed

Cerus: Q3 Earnings Snapshot

Cerus Corp. reported a Q3 loss of $550,000, or less than 1 cent per share, with revenue of $57.7 million. The company expects full-year revenue between $229 million and $231 million.

finance.yahoo.com1 min
NOV 2
$CERSMedAI 8/10

Cerus' blood-safety system meets main goal in late-stage trial

Cerus Corp reported that its Intercept blood-safety technology met the main goal in a late-stage trial, showing treated red blood cells performed as well as conventional ones in transfusions. The study found no significant difference in adverse events, though some patients developed temporary antibodies. The technology is not yet FDA-approved.

finance.yahoo.com4 min
NOV 2
$CERSMed

Cerus Corporation Announces Third Quarter 2026 Financial Results

CERUS CORP (CERS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cerus Corporation Announces Third Quarter 2026 Financial Results Third quarter 2026 total revenue of $64.0 million; third quarter 2026 product revenue of $57.7 million, +10% Y/Y Announced positive topline Phase 3 RedeS results of the INTERCEPT Blood System for red bl

SEC EDGAR 8-K2 min
NOV 2
MedAI 8/10

Treated red blood cells performed no worse than conventional cells on hemoglobin gains in Cerus’ Phase 3 trial.

Cerus Corporation reported that its INTERCEPT Red Blood Cells (RBCs) met the primary efficacy endpoint in a Phase 3 trial, showing non-inferiority to conventional RBCs in adjusted hemoglobin increment. The study also met primary safety endpoints, with no significant differences in treatment-emergent adverse events between the treatment and control arms. Cerus plans to submit full study results for peer-reviewed publication and presentation at scientific meetings.

stocktitan.net2 min